期刊文献+

遗忘型轻度认知功能损害患者血清脑源性神经营养因子及血浆组织型纤溶酶原激活剂水平变化及其临床意义 被引量:2

Changes and its clinical significance of serum brain-derived neurotrophic factor level and plasma tissue plasminogen activator level in patients with amnestic mild cognitive impairment
下载PDF
导出
摘要 目的探讨遗忘型轻度认知功能损害(aMCI)患者血清脑源性神经营养因子(BDNF)和血浆组织型纤溶酶原激活剂(t-PA)水平变化及其与aMCI发病的关系。方法应用多维度神经心理测试评估99例aMCI患者和99名正常对照者的神经认知功能;采用酶联免疫吸附法测定血清BDNF和血浆t-PA水平,并进行相关性分析。结果(1)aMCI组神经认知功能测试成绩明显低于正常对照组(均P〈0.01),尤以反映情节记忆的听觉词语记忆测试(AVMT)的延迟回忆受损最明显。(2)aMCI组血清BDNF水平[4.37(0.02-14.54)ng/ml]明显低于正常对照组[4.82(1.06-33.12)ng/ml](P〈0.05),血浆t-PA水平[(6.98±3.25)ng/ml]明显高于正常对照组[(6.18±2.32)ng/ml](P〈0.05)。(3)aMCI患者血清BDNF水平与血浆t-PA不相关;血清BDNF和血浆t-PA水平均与AVMT的延迟回忆显著相关(r=0.264,P〈0.01;r=-0.216,P〈0.05)。结论aMCI患者AVMT延迟回忆受损最明显;血清BDNF和血浆t-PA水平的变化与aMCI的认知功能损害密切相关。 Objective To investigate the changes and its clinical significance of serum brain-derived neurotrophic factor (BDNF) level and plasma tissue plasminogen activator( t-PA ) level in patients with amnestic mild cognitive impairment (aMCI). Methods 99 aMCI patients (aMCI group) and 99 matched normal controls (NC group) were recruited for the present study. Multi-dimension neuropsychologic tests were used to extensively assess cognitive function of subjects. An enzyme-linked immunosorbent assay was applied to measure serum BDNF level and plasma t-PA level. The correlation analysis between serum BDNF level and plasma t-PA level tested by ELISA and cognitive function were also made. Results ( 1 ) The results neuropsychologic tests in aMCI gnoup were significantly lower than those in NC group ( all P 〈 0. 01 ) , with the most impairment on delayed recall of the auditory verbal memory test (AVMT). (2) The serum level of BDNF in aMCI group [ 4.37 ( 0.02 - 14.54) ng/ml ] was significantly lower than that in NC group [ 4.82 ( 1.06 - 33.12 ) ng/ml ] ( P 〈 0. 05 ) ; inversely, the plasma level of t- PA in aMCI group [ ( 6.98 ± 3.25 ) ng/ml ] was significantly higher than that in NC group [ ( 6. 18 ± 2.32 ) ng/ml ( P 〈 0. 05 ). (3) The serum BDNF level was not related to the plasma t-PA level. There were significant correlations between the serum level of BDNF or the plasma level of t-PA and the score on delayed recall of AVMT (r = 0.264, P 〈 0. 01 ; r = - 0. 216, P 〈 0. 05) in aMCI group. Conclusions The damage in delaged recall of AVMT is most significant in patients with aMCI. There are colser ralations between the invasion of aMCI and the changes of serum BDNF level and plasma t-PA level.
出处 《临床神经病学杂志》 CAS 北大核心 2008年第3期198-200,共3页 Journal of Clinical Neurology
基金 江苏省科技厅自然科学基金重点项目(BK2006708)
关键词 遗忘 认知功能障碍 脑源性神经营养因子 组织型纤溶酶原激活剂 amnesia cognition disorder brain-derived neurotrophic factor tissue plasminogen activator
  • 相关文献

参考文献11

  • 1Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome [ J]. Arch Neurol, 1999, 56: 303.
  • 2Peng SY, Wuu J, Mufson E J, et al. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease [ J ]. J Neurochem, 2005, 93 : 1412.
  • 3Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration [J]. J Neurosci, 2003, 23:8867.
  • 4Aggarwal NT, Wilson RS, Beck TL, et al. Mild cognitive impairment in different functional domains and incident Alzheimer's disease [J].J Neurol Neurosurg Psychiatry, 2005, 76: 1479.
  • 5Pang PT, Teng HK, Zaitsev E,et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity [ J ]. Science, 2004, 306: 487.
  • 6Selkoe D.I. Alzheimer's disease is a synaptic failure [J]. Science, 2002, 298 : 789.
  • 7Counts SE, Nadeem M, Lad SP. Differential expression of synaptie proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment [ J]. J Neuropathol Exp Neurol, 2006, 65 : 592.
  • 8Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets [ J ]. Neurosci Let, 2002, 328: 261.
  • 9Laske C, Stransky E, Leyhe T, et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls [J]. J Psychiatric Res, 2007, 41: 387.
  • 10薛寿儒,杨小旺.血小板β-淀粉样肽前体蛋白免疫强度及异构体比率对Alzheimer病的诊断价值[J].临床神经病学杂志,2007,20(3):176-178. 被引量:5

二级参考文献7

  • 1丁新生.重视Alzheimer病的诊治[J].临床神经病学杂志,2005,18(4):241-243. 被引量:17
  • 2Padovani A,Borroni B,Colciaghi F,et al.Platelet amyloid precursor protein forms in AD:a peripheral diagnostic tool and a pharmacological target[J].Mechanisms Ageing Development,2001,122:1997.
  • 3Li QX,White S,Tanner JE,et al.Secretion of Alzheimer's disease Aβ amyloid peptide by activated human platelets[J].Lab Invest,1998,78:461.
  • 4Borroni B,Volpi R,Martini G,et al.Peripheral blood abnormalities in Alzheimer Disease:evidence for early endothelial dysfunction[J].Alzh Diss Ass Disorders,2002,16:150.
  • 5Borroni B,Colciaghi F,Lenzi GL,et al.High cholesterol affects platelet APP processing in controls and in AD patients[J].Neurobiology Aging,2003,24:631.
  • 6DiLuca M,Colciaghi F,Pastorino L,et al.Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease:the ease of amyloid precursor protein[J].Eur J Pharmaco,2000,405:277.
  • 7Zubenko GS,Kopp U,Seto T,et al.Platelet membrane fluidity individuals at risk for Alzheimer disease:a comparison of results from fluorescene spectroscopy and electron spin responce spectroscopy[J].Psychopharmacology,1999,145:175.

共引文献4

同被引文献28

  • 1Riemenschneider M, Lautenschlager N, Wagenpfeil S, et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002; 59 (11) : 1729-1734.
  • 2Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology, 2002; 59 (4) : 627-629.
  • 3Buerger K, Teipel SJ, Zinkowski R, et al. Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment. Neurosci Lett. 2005 ; 391 ( 1-2 ) : 48-50.
  • 4Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry, 2004 ; 61 ( 1 ) : 95-102.
  • 5Boban M, GrbicK, Mladinov M, et al. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia. Coil Antropol. 2008 ; 32 Suppl 1 : 31-36.
  • 6Hu YY, He SS, Wang X, et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol. 2002 ; 160 (4) : 1269-1278.
  • 7Tarkowski E, Andreasen N, Tarkowski A, et al. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry, 2003; 74 (9) : 1200-1205.
  • 8Ji JP, Meng R, Sun YX, et al. Cerebrospinal fluid tau, Abetal-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett. 2005 ; 383 (1-2) : 12-16.
  • 9Rosenberg RN, Baskin F, Fosmire JA. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol. 1997; 54 (2) : 139-144.
  • 10Laske C, Stransky E, Leyhe T, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. Neural Transm.2006; 113 (9): 1217-1224.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部